Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atomoxetine Effect on Attention, Executive Function, and Quality of Life in Veterans With Posttraumatic Stress Disorder

Next Previous
Trial Profile

Atomoxetine Effect on Attention, Executive Function, and Quality of Life in Veterans With Posttraumatic Stress Disorder

Status: Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use

Most Recent Events

  • 06 Jun 2025 Planned End Date changed from 31 Jan 2029 to 31 Jul 2029.
  • 06 Jun 2025 Planned primary completion date changed from 31 Jan 2029 to 30 Apr 2029.
  • 06 Jun 2025 Planned initiation date changed from 1 Jun 2025 to 1 Aug 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top